Total Payments
$5,791
2023 Payments
$56.01
Companies
55
Transactions
272
Medicare Patients
2,818
Medicare Billing
$378,425
Payment Breakdown by Category
Food & Beverage$5,466 (94.4%)
Education$324.56 (5.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,466 | 261 | 94.4% |
| Education | $324.56 | 11 | 5.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $902.35 | 45 | $0 (2022) |
| Pharmacyclics LLC, An AbbVie Company | $487.83 | 16 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $487.10 | 23 | $0 (2022) |
| Celgene Corporation | $408.36 | 23 | $0 (2020) |
| GENZYME CORPORATION | $396.65 | 6 | $0 (2022) |
| Genentech USA, Inc. | $306.85 | 20 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $288.61 | 20 | $0 (2020) |
| PFIZER INC. | $178.66 | 12 | $0 (2020) |
| Amgen Inc. | $172.62 | 11 | $0 (2019) |
| Janssen Biotech, Inc. | $171.99 | 8 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $56.01 | 2 | Pharmacyclics LLC, An AbbVie Company ($31.71) |
| 2022 | $660.49 | 9 | E.R. Squibb & Sons, L.L.C. ($244.03) |
| 2021 | $762.98 | 10 | GENZYME CORPORATION ($250.00) |
| 2020 | $472.96 | 23 | E.R. Squibb & Sons, L.L.C. ($47.96) |
| 2019 | $1,428 | 75 | Celgene Corporation ($207.52) |
| 2018 | $1,522 | 99 | E.R. Squibb & Sons, L.L.C. ($290.68) |
| 2017 | $887.96 | 54 | E.R. Squibb & Sons, L.L.C. ($132.31) |
All Payment Transactions
272 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2023 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: Oncology | ||||||
| 02/10/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $31.71 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $20.25 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: ONCOLOGY | ||||||
| 03/29/2022 | GlaxoSmithKline, LLC. | BLENREP (Biological) | Food and Beverage | In-kind items and services | $124.74 | General |
| Category: ONCOLOGY | ||||||
| 03/23/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 03/08/2022 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Hematology | ||||||
| 03/03/2022 | GENZYME CORPORATION | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $88.23 | General |
| Category: Oncology | ||||||
| 01/19/2022 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $119.03 | General |
| Category: Hematology | ||||||
| 01/10/2022 | Teleflex LLC | ARROW (Device) | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: Interventional Access | ||||||
| 11/30/2021 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $124.80 | General |
| Category: Oncology | ||||||
| 11/23/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Education | In-kind items and services | $92.00 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Education | In-kind items and services | $48.35 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Education | In-kind items and services | $48.35 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Education | In-kind items and services | $31.28 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Education | In-kind items and services | $31.28 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 11/10/2021 | GENZYME CORPORATION | CABLIVI (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Hematology | ||||||
| 10/14/2021 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 12/03/2020 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $45.57 | General |
| Category: Oncology | ||||||
| 10/30/2020 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $19.53 | General |
| Category: ONCOLOGY | ||||||
| 10/15/2020 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $28.48 | General |
| Category: Oncology | ||||||
| 08/13/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $26.50 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 226 | 310 | $93,989 | $29,218 |
| 2022 | 4 | 318 | 424 | $136,234 | $42,273 |
| 2021 | 8 | 659 | 5,759 | $243,878 | $65,744 |
| 2020 | 25 | 1,615 | 41,954 | $1.0M | $241,190 |
Total Patients
2,818
Total Services
48,447
Medicare Billing
$378,425
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 43 | 70 | $23,030 | $7,606 | 33.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 57 | 98 | $23,912 | $7,230 | 30.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 45 | 45 | $19,170 | $5,158 | 26.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 17 | 29 | $10,150 | $3,448 | 34.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 34 | 34 | $11,492 | $2,862 | 24.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 19 | $3,610 | $1,879 | 52.1% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 15 | 15 | $2,625 | $1,035 | 39.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 43 | 68 | $24,229 | $9,526 | 39.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 59 | 89 | $27,412 | $8,498 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 110 | 153 | $36,294 | $8,072 | 22.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 36 | 41 | $19,141 | $6,372 | 33.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 30 | 30 | $14,164 | $4,752 | 33.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 20 | 20 | $8,900 | $2,794 | 31.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 23 | $6,094 | $2,258 | 37.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 77 | 122 | $37,576 | $14,336 | 38.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 110 | 165 | $36,960 | $13,831 | 37.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2021 | 14 | 4,780 | $100,380 | $13,365 | 13.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 61 | 82 | $24,682 | $11,293 | 45.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 68 | 79 | $18,723 | $6,308 | 33.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 17 | 17 | $7,565 | $2,518 | 33.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 146 | 249 | $7,470 | $1,935 | 25.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 14 | 15 | $2,220 | $1,034 | 46.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 129 | 202 | $3,838 | $606.00 | 15.8% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 23 | 48 | $4,464 | $518.28 | 11.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 209 | 511 | $153,811 | $60,417 | 39.3% |
About Dr. Michael Mikhail, M.D
Dr. Michael Mikhail, M.D is a Medical Oncology healthcare provider based in Malvern, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043384035.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Mikhail, M.D has received a total of $5,791 in payments from pharmaceutical and medical device companies, with $56.01 received in 2023. These payments were reported across 272 transactions from 55 companies. The most common payment nature is "Food and Beverage" ($5,466).
As a Medicare-enrolled provider, Mikhail has provided services to 2,818 Medicare beneficiaries, totaling 48,447 services with total Medicare billing of $378,425. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology, Medical Oncology
- Location Malvern, PA
- Active Since 11/20/2006
- Last Updated 07/10/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1043384035
Products in Payments
- OPDIVO (Biological) $551.44
- IMBRUVICA (Drug) $369.39
- CALQUENCE (Drug) $305.29
- KEYTRUDA (Biological) $257.61
- Abraxane (Drug) $207.05
- ADCETRIS (Biological) $184.82
- Imbruvica (Drug) $176.33
- Pomalyst (Drug) $174.90
- TIBSOVO (Drug) $159.26
- REBLOZYL (Biological) $140.87
- TEGSEDI (Drug) $132.04
- LIBTAYO (Biological) $130.57
- CABLIVI (Biological) $125.00
- BLENREP (Biological) $124.74
- Avastin (Biological) $115.49
- TAGRISSO (Drug) $113.41
- XTANDI (Drug) $99.93
- Revlimid (Drug) $82.73
- Neulasta (Biological) $76.82
- ZEJULA (Drug) $72.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.